Prevention of type 1 diabetes mellitus using a novel vaccine
Authors:
Open Access
- 29 November 2010
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 2 (1) , 9-16
Abstract
Type 1 diabetes mellitus (T1DM) affects 1 in 300 people and the incidence of the disease is rising worldwide. T1DM is caused by chronic autoimmune destruction of the insulin-producing β-cells. The exact etiology and primary auto-antigen are not yet known. The autoimmune, chronic, and progressive nature of the disease raises the possibility of intervention, preferably by slowing down or stopping the destruction of the β-cells as early as the prediabetic stage. Since the 1980s, several attempts have been made to maintain β-cell function using immunosuppressive agents, immune modulation such as plasmapheresis, cytokine therapy, or antibody treatment. These agents were not diabetes specific; the occasionally observed beneficial effect did not compensate for the often very severe side effects. According to the latest assumption, the administration of diabetes-specific auto-antigens can elicit tolerance, which can prevent the destruction of the β-cells, hopefully without serious side effects. The authors summarize current understanding of the immunology of T1DM, review the trials on prevention, and discuss their vaccination study.Keywords
This publication has 47 references indexed in Scilit:
- Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapyJournal of Autoimmunity, 2010
- Are T-Cell Responses to GAD65 Influential in Type 1 Diabetes?Diabetes, 2009
- Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2009
- No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 DiabetesDiabetes Care, 2009
- Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration studyThe Lancet, 2009
- Insulin – a primary autoantigen in type 1 diabetes?Trends in Molecular Medicine, 2005
- Continuous glucose monitoring and closed‐loop systemsDiabetic Medicine, 2005
- Prediabetes in ChildrenPediatric Drugs, 2003
- Development of Type 1 Diabetes despite Severe Hereditary B-Cell DeficiencyNew England Journal of Medicine, 2001
- Update on Major Trials for the Prevention of Type I Diabetes Mellitus: The American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT)Journal of Pediatric Endocrinology and Metabolism, 2001